Vistagen Therapeutics, Inc. (VTGN): EBITDA
-$71.93M
Year ended 2026-03-31
-$69.46M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$71.93M | n/m | 2026-06-15, From 2025-04-01 |
| 2025-03-31 | -$55.82M | n/m | 2026-06-15, From 2024-04-01 |
| 2024-03-31 | -$32.89M | n/m | 2025-06-17, From 2023-04-01 |
| 2023-03-31 | -$59.14M | n/a | 2024-06-11, From 2022-04-01 |
| No annual figure between 2021-03-31 and 2023-03-31. | |||
| 2021-03-31 | -$17.82M | n/m | 2022-06-23, From 2020-04-01 |
| 2020-03-31 | -$20.70M | n/m | 2021-06-29, From 2019-04-01 |
| 2019-03-31 | -$24.47M | n/m | 2020-06-29, From 2018-04-01 |
| 2018-03-31 | -$14.12M | n/m | 2019-06-25, From 2017-04-01 |
| 2017-03-31 | -$10.19M | n/m | 2018-06-26, From 2016-04-01 |
| 2016-03-31 | -$17.80M | n/m | 2017-06-29, From 2015-04-01 |
| 2015-03-31 | -$6.72M | n/m | 2016-06-24, From 2014-04-01 |
| 2014-03-31 | -$4.97M | n/m | 2015-06-29, From 2013-04-01 |
| 2013-03-31 | -$6.76M | n/m | 2014-06-25, From 2012-04-01 |
| 2012-03-31 | -$9.00M | n/m | 2013-07-18, From 2011-04-01 |
| 2011-03-31 | -$6.52M | n/a | 2012-07-02, From 2010-04-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$71.93M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$6.83M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$22.49M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2024-12-31 | -$3.63M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$15.79M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$57.85M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | -$7.05M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$16.15M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | -$11.92M | n/m |
Compare VTGN, IGC, LGVN, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗